ALKBH2 Protein: A Promising Drug Target Or Biomarker (G121642)

Target Name: ALKBH2

NCBI ID: G121642

ALKBH2

ALKBH2 Protein: A Promising Drug Target Or Biomarker

ALKBH2 (ALKB2_HUMAN), a protein that belongs to the ALKBH2 family, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has generated a lot of interest in the scientific community.

The ALKBH2 protein is a 21-kDa protein that is expressed in most tissues of the body. It is a key regulator of the bacterial flagellum, which is a protein that is responsible for the movement of cells. The ALKBH2 protein has been shown to play a crucial role in the regulation of bacterial flagellum length and stability.

Recent studies have also shown that the ALKBH2 protein is involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to promote the migration of cancer cells and the development of neurodegenerative diseases.

In addition to its role in cellular processes, the ALKBH2 protein has also been shown to play a role in the regulation of inflammation. It has been shown to contribute to the regulation of immune cell function and to play a role in the development of autoimmune disorders.

Given its unique structure and function, the ALKBH2 protein has generated a lot of interest as a potential drug target or biomarker. Studies have shown that blocking the ALKBH2 protein can be an effective way to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising strategies for targeting the ALKBH2 protein is the use of small molecules, such as inhibitors or modulators. Studies have shown that various small molecules have the potential to inhibit the ALKBH2 protein's activity, and that these compounds may be effective in treating various diseases.

In addition to small molecules, the ALKBH2 protein has also been shown to be an attractive target for monoclonal antibodies (MCAs). MCAs are laboratory-produced antibodies that are single in their structure and can be used to target specific proteins in the body. Studies have shown that the ALKBH2 protein is an attractive target for MCAs, and that these antibodies may be effective in treating various diseases.

Another promising strategy for targeting the ALKBH2 protein is the use of genetic modification. Studies have shown that genetic modification can be used to alter the ALKBH2 protein's structure and function, and that these changes may be useful in targeting the protein.

Overall, the ALKBH2 protein is a unique and promising target for various diseases. Its structure and function make it an attractive target for small molecules, monoclonal antibodies, and genetic modification. Further research is needed to fully understand the role of the ALKBH2 protein in the regulation of cellular processes and the development of various diseases.

In conclusion, the ALKBH2 protein is a promising target for various diseases. Its unique structure and function make it an attractive target for small molecules, monoclonal antibodies, and genetic modification. Further research is needed to fully understand the role of the protein in the regulation of cellular processes and the development of various diseases.

Protein Name: AlkB Homolog 2, Alpha-ketoglutarate Dependent Dioxygenase

Functions: Dioxygenase that repairs alkylated nucleic acid bases by direct reversal oxidative dealkylation. Can process both double-stranded (ds) and single-stranded (ss) DNA substrates, with a strong preference for dsDNA (PubMed:12486230, PubMed:12594517, PubMed:16174769, PubMed:20714506, PubMed:25797601, PubMed:23972994). Uses molecular oxygen, 2-oxoglutarate and iron as cofactors to oxidize the alkyl groups that are subsequently released as aldehydes, regenerating the undamaged bases. Probes the base pair stability, locates a weakened base pair and flips the damaged base to accommodate the lesion in its active site for efficient catalysis (PubMed:18432238, PubMed:22659876). Repairs monoalkylated bases, specifically N1-methyladenine and N3-methylcytosine, as well as higher order alkyl adducts such as bases modified with exocyclic bridged adducts known as etheno adducts including 1,N6-ethenoadenine, 3,N4-ethenocytosine and 1,N2-ethenoguanine (PubMed:12486230, PubMed:12594517, PubMed:16174769, PubMed:20714506, PubMed:25797601, PubMed:23972994, PubMed:26408825). Acts as a gatekeeper of genomic integrity under alkylation stress. Efficiently repairs alkylated lesions in ribosomal DNA (rDNA). These lesions can cause ss- and dsDNA strand breaks that severely impair rDNA transcription (PubMed:23972994). In a response mechanism to DNA damage, associates with PCNA at replication forks to repair alkylated adducts prior to replication (PubMed:19736315, PubMed:26408825)

The "ALKBH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALKBH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets